Updated: Oct 19
Medically reviewed by ChinaCureLink Team
Table of Content
Why This Case Matters
This case follows Dewi (alias), a 25-year-old ovarian cancer patient from Indonesia whose stage IV disease — an 18-centimeter pelvic mass with liver, spleen, and peritoneal spread — had reached a treatment dead end at home, and who traveled roughly 3,000 km to a licensed oncology hospital in Guangzhou for a staged treatment plan that ultimately made surgery possible. For international patients across Southeast Asia facing advanced gynecological cancers considered inoperable, ChinaCureLink can help evaluate access to this same combined intervention-and-surgery approach.
Key Takeaways |
|
Patient Background
In February 2025, Dewi began experiencing sudden abdominal distension and pain. Seeking answers in Malaysia, she received devastating news: a CT scan revealed a pelvic mass measuring nearly 18 centimeters at its largest dimension, and pathology confirmed low-grade serous ovarian carcinoma that had already reached FIGO stage IV — with metastases to her liver and spleen, spread across her peritoneum, and extensive ascites. Her situation was further complicated by local invasion into the rectum and blockage of both ureters. With treatment options in her home region reaching a dead end, she and her family began searching for another path forward.
The Care Team and Approach
Through a dedicated Indonesia-China medical referral pathway, Dewi traveled to a licensed oncology hospital in Guangzhou in March 2025. The hospital's own follow-up imaging confirmed the scale of what she was facing: extensive tumor invasion into the tissue surrounding her uterus, with multiple active metastatic lesions throughout her abdominal cavity.
Given how advanced and widespread her disease was, a joint team of interventional radiology and oncology specialists determined that immediate radical surgery wasn't feasible. Instead, they planned a staged approach: three rounds of arterial infusion chemotherapy combined with intraperitoneal treatment, delivered on March 24, April 14, and May 7, 2025. The bridging treatment worked quickly — her ascites decreased significantly and her abdominal distension eased, opening a genuine window to consider surgery.
On June 11, 2025, Director Lin Meihua (pseudonym) of the hospital's International Medical Center convened an eight-specialist multidisciplinary team spanning gynecology, general surgery, and interventional radiology for a thorough preoperative evaluation. Despite persistent liver and spleen metastases, the team found that Dewi's tumor markers had dropped and her overall physical condition had improved enough to meet the criteria for surgery. They planned a combined procedure: ovarian cancer debulking surgery paired with cryoablation of a liver metastasis.
On June 13, 2025, Professor Chen Yifan (pseudonym) and Professor Tian Wei (pseudonym) led a four-hour surgery: a total hysterectomy, removal of both ovaries and fallopian tubes, and excision of pelvic tumor tissue, the omentum, and peritoneal metastatic nodules. The team also performed argon-helium cryoablation on a 4.5-centimeter metastatic tumor in the liver, carefully released extensive bowel adhesions, and drained roughly 1,000 milliliters of ascites during the procedure.
Treatment Timeline/ Process
Before Treatment (Malaysia)
February 2025: Sudden abdominal distension and pain; diagnosed with stage IV low-grade serous ovarian carcinoma — an 18-cm pelvic mass, liver and spleen metastases, peritoneal spread, extensive ascites, rectal invasion, and bilateral ureteral blockage
Local treatment options reached a dead end
At the Hospital (China)
March 2025: Traveled roughly 3,000 km to Guangzhou through a dedicated Indonesia-China referral pathway; follow-up imaging confirmed the extent of her disease
March 24 – May 7, 2025: Underwent three rounds of arterial infusion chemotherapy with concurrent intraperitoneal treatment; ascites and abdominal distension improved rapidly
June 11, 2025: An 8-specialist multidisciplinary team confirmed her eligibility for surgery
June 13, 2025: Underwent a four-hour combined surgery — total hysterectomy, bilateral removal of ovaries and fallopian tubes, tumor debulking, and cryoablation of a liver metastasis
Recovery
By the fourth day after surgery, recovering well and speaking comfortably with her family
Outcome
By the fourth day after her surgery, Dewi was recovering well, alert, and speaking comfortably with her family — a striking contrast to the critical, treatment-resistant state she'd arrived in just months earlier. Her case reflects a successful surgical debulking and early post-operative recovery; longer-term outcomes for stage IV ovarian cancer depend on continued follow-up and monitoring, which remain part of her ongoing care.
How ChinaCureLink Can Help International Patients to Access This Treatment
Dewi's case reflects exactly the kind of complex, cross-border care pathway ChinaCureLink exists to support — the hospital's own Indonesia-China medical service program has already coordinated care for more than 100 patients across Southeast Asia facing advanced gynecological cancers. For international patients whose cancer has been called inoperable at home, ChinaCureLink helps get a specialized case review and connects patients with hospitals in China experienced in staged intervention-and-surgery protocols, coordinating medical record translation, hospital matching, and every logistical step — including interpretation, accommodation, and culturally appropriate support — from first inquiry through treatment and recovery.
Get a Second Opinion Before Fly to China
For suitable cases, ChinaCureLink can then coordinate an online consultation with the specialist to discuss the technical treatment details directly. The purpose is to help the patient understand which treatment option and which specialist center may be most appropriate before making an international treatment decision.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
★★★★☆ Sarah Zhang · Canada· Jul 2024 · Verified “The interpreter during the video call was fantastic — super professional and answered all our questions clearly and quickly. The professor was also very patient and gave us detailed and honest guidance on our treatment options.” |
★★★★★ Andrew Goh · Singapore · Aug 2024 · Verified “My first contact with Medebound was over a year ago. Jason has always been responsive, even when I wasn't ready to proceed. When I finally did, the consultation was seamlessly arranged and the specialist was outstanding.” |
★★★★★ Daniel Wong · Singapore · Aug 2024 · Verified “I have dry eye and nothing seemed to be working, even with different medications. I heard about a medication from the U.S. that’s supposed to be really effective, but I didn’t want to try it without talking to a doctor first. MEDEBOUND connected me with a top ophthalmologist in the U.S. and it was so reassuring to get their expert advice.” |
★★★★☆ Pongsakorn · Thailand · Feb 2025 · Verified “Kiki at Medebound is amazing — so professional and helpful! They got my video consultation with an MD Anderson expert set up super fast, within just 5 working days. I am so grateful for their support.” |
Frequently Asked Questions
Can stage IV ovarian cancer with liver and spleen metastases still be treated with surgery?
It depends on the case. As Dewi's story shows, bridging treatment like arterial infusion chemotherapy can sometimes reduce tumor burden enough to make surgery possible, even in advanced cases initially considered inoperable. A multidisciplinary evaluation is needed to determine eligibility.
What is argon-helium cryoablation and how is it used alongside cancer surgery?
Argon-helium cryoablation uses extreme cold to destroy tumor tissue, and can be combined with traditional surgery to treat metastases in organs like the liver during the same procedure, without requiring separate surgical removal of that tissue.
How can international patients from Southeast Asia access this kind of advanced gynecological cancer treatment in China?
Access typically starts with a case review, where medical records, imaging, and pathology are submitted for evaluation. ChinaCureLink coordinates this process and helps match patients with hospitals experienced in complex, multidisciplinary cancer care.
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific.
Disclaimer
This account reflects one patient's individual experience, which will vary by case, diagnosis stage, and other clinical factors. ChinaCureLink facilitates access to hospitals and treatment coordination — we do not provide medical care ourselves, and this content is not medical advice. Patients and families should consult a qualified gynecologic oncologist before making treatment decisions.
